Two innovative medical nutrition products developed by the knowledge-based company Pazhouhesh Gostaran Taghzieh Asan—FastMeal Peptide and FastMeal Renal—were officially unveiled during the 10th Intensive Care Congress (ICU) held at Milad Hospital in Tehran.
According to Dr. Vahid Mofid, CEO of Pazhouhesh Gostaran Taghzieh Asan, FastMeal Peptide is Iran’s first locally produced peptide-based enteral nutrition formula, developed using hydrolyzed whey protein (WPH). This complete and specialized nutritional solution has been designed in accordance with global standards to meet the macro- and micronutrient needs of patients suffering from gastrointestinal disorders, malabsorption, or those requiring clinical nutritional support.
Dr. Mofid stated that up to 30% of hospitalized patients experience varying degrees of malnutrition, often due to impaired digestion or absorption. “FastMeal Peptide is formulated with hydrolyzed whey protein for rapid absorption, MCT oil for immediate energy, inulin for gut health, omega-3 and 9 fatty acids for anti-inflammatory and immune support, L-carnitine for energy metabolism, and 28 essential vitamins and minerals,” he said.
He also announced the upcoming launch of FastMeal Peptide Junior, a version tailored specifically for pediatric patients with conditions such as celiac disease, cystic fibrosis, or short bowel syndrome, which often prevent effective nutrient absorption.
The second product introduced at the congress, FastMeal Renal, is the first Iranian formula designed specifically for patients with chronic kidney disease (CKD). It features low protein content, high levels of monounsaturated fats (including omega-3s), and reduced levels of phosphorus, potassium, and sodium, alongside vital vitamins such as B6, B9, and D3.
According to Dr. Mofid, FastMeal Renal addresses the specialized nutritional needs of CKD patients and eliminates the country’s dependency on costly and often unstable imported products. He emphasized that these two formulas could prevent the annual outflow of nearly $10 million in foreign currency by replacing imported clinical nutrition products.
“These formulations are not just supplements; they are reliable, scientifically developed tools for managing complex medical nutrition challenges such as malabsorption, digestive disorders, and renal insufficiency,” he added.
Designed by a multidisciplinary team of nutritionists, pharmacists, and biotechnology experts, FastMeal products combine international guidelines with localized expertise. They are already proving effective in critical hospital settings, particularly for ICU patients, cancer recovery, and those with severe weight loss or chronic conditions.
“By offering these products at a fraction of the cost of imports—without compromising quality or palatability—our company has provided a sustainable domestic solution to one of the most pressing therapeutic nutrition challenges in the country,” Dr. Mofid concluded.
